Table 1.
Effect of compounds 107–110 on different sPLA2 activities a.
| Compound | N. naja Venom %I (10 μM) | Pancreas %I (10 μM) | Human Synovial %I (10 μM) IC50 (μM) | RAPb + Zymosan %I (10 μM) | Bee Venom %I (10 μM) IC50 (μM) |
|---|---|---|---|---|---|
| 107 | 0.5 ± 0.5 | 18.0 ± 8.1 | 40.1 ± 7.7 d | 17.1 ± 4.6 | 33.1 ± 6.0 c |
| 108 | 0.4 ± 0.4 | 14.2 ± 5.1 | 34.6 ± 5.8 d | 17.9 ± 4.2 | 32.2 ± 6.0 c |
| 109 | 3.1 ± 2.2 | 9.1 ± 3.5 | 40.4 ± 5.7 d | 30.9 ± 5.3 c | 36.2 ± 5.4 d |
| 110 | 0.0 ± 0.0 | 7.6 ± 4.0 | 48.2 ± 3.8 d | 19.6 ± 5.4 | 37.6 ± 6.5 c |
| manoalide | 17.0 ± 1.7 c | 32.3 ± 2.7 d | 93.2 ± 0.2 d 3.9 | 38.4 ± 0.5 d | 62.5 ± 3.8 d 7.5 |
a Results show percentages of inhibition at 10 μM and IC50 (μM) values determined only for those compounds that reach 50% of inhibition. Mean ± S.E.M. (n = 6); b RAP: Rat air pouch PLA2; c p < 0.05; d p < 0.01.